CO2021005140A2 - Formas mórficas de los inhibidores del factor d del complemento - Google Patents

Formas mórficas de los inhibidores del factor d del complemento

Info

Publication number
CO2021005140A2
CO2021005140A2 CONC2021/0005140A CO2021005140A CO2021005140A2 CO 2021005140 A2 CO2021005140 A2 CO 2021005140A2 CO 2021005140 A CO2021005140 A CO 2021005140A CO 2021005140 A2 CO2021005140 A2 CO 2021005140A2
Authority
CO
Colombia
Prior art keywords
complement factor
inhibitors
morphic forms
forms
morphic
Prior art date
Application number
CONC2021/0005140A
Other languages
English (en)
Inventor
Avinash Phadke
Akihiro Hashimoto
Mark Andres
Original Assignee
Achillion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achillion Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Publication of CO2021005140A2 publication Critical patent/CO2021005140A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención proporciona formas estables y altamente cristalinas del Compuesto 3 inhibidor del Factor D del Complemento para aplicaciones terapéuticas.
CONC2021/0005140A 2018-09-25 2021-04-22 Formas mórficas de los inhibidores del factor d del complemento CO2021005140A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862736294P 2018-09-25 2018-09-25
US201862757565P 2018-11-08 2018-11-08
US201862760520P 2018-11-13 2018-11-13
US201962796776P 2019-01-25 2019-01-25
PCT/US2019/053012 WO2020069024A1 (en) 2018-09-25 2019-09-25 Morphic forms of complement factor d inhibitors

Publications (1)

Publication Number Publication Date
CO2021005140A2 true CO2021005140A2 (es) 2021-04-30

Family

ID=69949508

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0005140A CO2021005140A2 (es) 2018-09-25 2021-04-22 Formas mórficas de los inhibidores del factor d del complemento

Country Status (11)

Country Link
US (1) US11807627B2 (es)
EP (1) EP3856164A4 (es)
JP (1) JP2022502500A (es)
KR (1) KR20210093855A (es)
CN (1) CN112996497A (es)
AU (1) AU2019346464A1 (es)
BR (1) BR112021005506A2 (es)
CA (1) CA3114039A1 (es)
CO (1) CO2021005140A2 (es)
MX (1) MX2021003425A (es)
WO (1) WO2020069024A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AU2018227849B2 (en) 2017-03-01 2022-04-28 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
US11807627B2 (en) 2018-09-25 2023-11-07 Achillon Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
JP7471300B2 (ja) * 2018-12-17 2024-04-19 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体介在性疾患を治療するための的を絞った投与

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
CA2248772C (en) 1996-03-13 2007-06-12 John D. Lambris Novel peptides which inhibit complement activation
AU7808198A (en) 1997-06-03 1998-12-21 Biocryst Pharmaceuticals, Inc. Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
AU754716B2 (en) 1998-03-26 2002-11-21 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists
JP2002524463A (ja) 1998-09-09 2002-08-06 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規な芳香族インヒビター
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
AU6868900A (en) 1999-09-03 2001-04-10 Ajinomoto Co., Inc. Novel processes for preparing oxazepine derivatives
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
NZ537853A (en) 2002-07-16 2007-02-23 Amura Therapeutics Ltd Inhibitors of cathepsin K and related cysteine protesases of the CA clan
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
AU2003275075A1 (en) 2002-09-20 2004-04-08 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved activity
FR2845382A1 (fr) 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
AU2003902946A0 (en) 2003-06-12 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
MXPA06010756A (es) 2004-03-24 2006-12-15 Jerini Ag Nuevos compuestos para la inhibicion de la angiogenesis y su uso.
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US20080075728A1 (en) 2004-07-20 2008-03-27 Walter Newman Combination Therapies Of Hmgb And Complement Inhibitors Against Inflammation
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP2377877B1 (en) 2005-11-28 2018-03-28 The Trustees Of The University Of Pennsylvania Potent compstatin analogs
EP1976829A2 (en) 2005-12-12 2008-10-08 Genelabs Technologies, Inc. N-(6-membered aromatic ring)-amido anti-viral compounds
DK2359834T5 (en) 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
EP2108642A1 (en) 2006-10-17 2009-10-14 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
RU2470918C2 (ru) 2007-01-15 2012-12-27 Сантен Фармасьютикал Ко., Лтд. НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ IκB КИНАЗЫ β
HUE026001T2 (en) 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
DK2238142T3 (da) 2007-12-24 2012-10-08 Janssen R & D Ireland Makrocykliske indoler som hepatitis C-virusinhibitorer
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
EP2837388A1 (en) 2008-08-05 2015-02-18 Novartis AG Compositions and methods for antibodies targeting complement protein C5
GB2469471B (en) 2009-04-14 2015-01-14 Skype Optimising communications
HUE035378T2 (en) 2009-05-01 2018-05-02 Univ Pennsylvania Compstatin with peptide framework and C-terminal modifications
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
CA2777013A1 (en) 2009-10-16 2011-04-21 Mochida Pharmaceutical Co., Ltd. Marker associated with non-alcoholic steatohepatitis
EA201290286A1 (ru) 2009-11-05 2013-01-30 Алексион Кембридж Корпорейшн Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза
EP2966075B1 (en) 2009-12-31 2019-02-27 Hutchison Medipharma Limited Certain triazolopyridines, compositions thereof and their use in the treatment of cancer.
DK2558446T5 (da) 2010-04-16 2019-12-09 Ac Immune Sa Nye forbindelser til behandling af sygdomme associerede med amyloid- eller amyloidlignende proteiner
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
WO2012006599A2 (en) 2010-07-09 2012-01-12 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
MX347391B (es) 2011-01-04 2017-04-25 Novartis Ag Compuestos de indol o análogos de los mismos útiles para el tratamiento de degeneración macular relacionada con la edad (amd).
ES2915265T3 (es) 2011-05-11 2022-06-21 Apellis Pharmaceuticals Inc Análogos de compstatina reactivos con células, de acción prolongada o dirigidos y usos de los mismos
HUE029326T2 (hu) 2011-05-27 2017-02-28 Achillion Pharmaceuticals Inc Szubsztituált alifánok, ciklofánok, heterafánok, heterofánok, hetero-heterafánok és metallocének, amelyek alkalmasak HCV fertõzések kezelésére
JP2014518223A (ja) 2011-06-20 2014-07-28 アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド 化合物とその治療用途
MX363606B (es) 2011-06-22 2019-03-28 Apellis Pharmaceuticals Inc Uso de inhibidores del complemento en trastornos crónicos.
US20130035392A1 (en) 2011-08-01 2013-02-07 Mcgeer Patrick L Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex
HUE047375T2 (hu) 2011-09-07 2020-04-28 Univ Pennsylvania Javított farmakokinetikai tulajdonságokkal rendelkezõ compstatin analógok
NZ742004A (en) 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
SG11201406973PA (en) 2012-05-04 2014-12-30 Novartis Ag Complement pathway modulators and uses thereof
RS61755B1 (sr) 2012-06-18 2021-05-31 Omeros Corp Kompozicije i postupci za inhibiciju masp-1 i/ili masp-2 i/ili masp-3 za tretman različitih bolesti i poremećaja
EA201590053A1 (ru) 2012-06-20 2015-08-31 Новартис Аг Модуляторы пути системы комплемента и их применение
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
AU2013282768A1 (en) 2012-06-28 2015-01-22 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
JP6273274B2 (ja) 2012-06-28 2018-01-31 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
JP6155332B2 (ja) 2012-06-28 2017-06-28 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
EP2867227B1 (en) 2012-06-28 2018-11-21 Novartis AG Complement pathway modulators and uses thereof
CN104603126B (zh) 2012-06-28 2017-05-31 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
WO2014002052A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
ITMI20121156A1 (it) 2012-06-29 2013-12-30 Consiglio Nazionale Ricerche Metodo di elaborazione di immagini di tomografia a coerenza ottica
WO2014002059A1 (en) 2012-06-29 2014-01-03 Novartis Ag CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
WO2014005150A1 (en) 2012-06-29 2014-01-03 Novartis Ag Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
JP6238980B2 (ja) 2012-07-12 2017-11-29 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
SG11201500377UA (en) 2012-09-10 2015-02-27 Hoffmann La Roche 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2014078734A2 (en) 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
DK2920201T3 (da) 2012-11-15 2020-04-14 Apellis Pharmaceuticals Inc Langtidsvirkende compstatin-analoger og relaterede sammensætninger og fremgangsmåder
US9773428B2 (en) 2012-12-11 2017-09-26 Fluidity Software, Inc. Computerized system and method for teaching, learning, and assessing step by step solutions to stem problems
EP2948480A4 (en) 2013-01-23 2016-12-07 Musc Found For Res Dev NATURAL ANTIBODY TARGETING CONSTRUCTS AND USES THEREOF
EP2970269B1 (en) 2013-03-14 2017-04-19 Novartis AG 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
WO2015009977A1 (en) 2013-07-18 2015-01-22 Novartis Ag Aminomethyl-biaryl derivatives as complement factor d inhibitors and uses thereof
JP2016169161A (ja) 2013-07-19 2016-09-23 大日本住友製薬株式会社 新規イミダゾピリジン化合物
JP6211701B2 (ja) 2013-08-07 2017-10-11 アレクシオン ファーマシューティカルズ， インコーポレイテッド 非典型溶血性尿毒症症候群のバイオマーカータンパク質
WO2015054569A1 (en) 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
WO2015066241A1 (en) 2013-10-30 2015-05-07 Novartis Ag 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
IL301427A (en) 2014-02-25 2023-05-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl, and heterocyclic compounds for the treatment of complement-mediated disorders
WO2016088082A1 (en) 2014-12-05 2016-06-09 Novartis Ag Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
WO2017024318A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AR105808A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035355A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
WO2017035415A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
WO2017035352A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of medical disorders
WO2017035413A2 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
WO2017035417A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of immune and inflammatory disorders
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
WO2017035418A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for treatment of immune and inflammatory disorders
WO2017035411A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of immune and inflammatory disorders
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035348A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of medical disorders
EP3386504A4 (en) 2015-12-11 2019-05-22 Lifesci Pharmaceuticals, Inc. THERAPEUTIC INHIBITOR COMPOUNDS
TWI791423B (zh) 2016-01-14 2023-02-11 美商卡默森屈有限公司 C3腎絲球病變之治療方法
WO2017127761A1 (en) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
TW202222786A (zh) 2016-02-01 2022-06-16 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
CN109414441A (zh) 2016-06-27 2019-03-01 艾其林医药公司 治疗医学障碍的喹唑啉和吲哚化合物
JOP20170154B1 (ar) 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
AU2018227849B2 (en) 2017-03-01 2022-04-28 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
US20190038623A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
US20200262897A1 (en) 2017-10-04 2020-08-20 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
US11807627B2 (en) 2018-09-25 2023-11-07 Achillon Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
JP7471300B2 (ja) 2018-12-17 2024-04-19 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体介在性疾患を治療するための的を絞った投与

Also Published As

Publication number Publication date
EP3856164A4 (en) 2022-07-13
EP3856164A1 (en) 2021-08-04
BR112021005506A2 (pt) 2021-06-15
CN112996497A (zh) 2021-06-18
WO2020069024A1 (en) 2020-04-02
CA3114039A1 (en) 2020-04-02
KR20210093855A (ko) 2021-07-28
US11807627B2 (en) 2023-11-07
AU2019346464A1 (en) 2021-04-08
MX2021003425A (es) 2021-07-16
JP2022502500A (ja) 2022-01-11
US20210332026A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
CO2021005140A2 (es) Formas mórficas de los inhibidores del factor d del complemento
CL2021003191A1 (es) Inhibidores de tead y usos de los mismos
CL2021003190A1 (es) Inhibidores de tead y usos de los mismos
UY37870A (es) Inhibidores de kras g12c y métodos para utilizarlos campo de la invención
MA53388A (fr) Inhibiteurs d'inflammasome nlrp3
CY1124483T1 (el) Συνθεσεις και μεθοδοι για την αναστολη της δραστικοτητας της αργινασης
CO2022002759A2 (es) Antagonistas de hpk1 y sus usos
CL2021000084A1 (es) Inhibidores de pd-1/pd-l1
ECSP22011692A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
CY1125065T1 (el) Αναστολεις mcl-1
CO2021004160A2 (es) Formas mórficas de los inhibidores del factor d del complemento
UY37744A (es) Inhibidores de kras g12c y métodos para su uso
CO2019001212A2 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos
CL2018000687A1 (es) Nuevos compuestos bicíclicos como inhibidores de atx.
EA201691421A1 (ru) Гетероарилы и их применение
MX2020003666A (es) Compuestos y composiciones para el tratamiento de trastornos hematologicos.
CO2021000049A2 (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
DK3833662T3 (da) Inhibitorer af protein-protein-interaktionen mellem KEAP-1-NRF2-
CL2023002223A1 (es) Inhibidores de cdk2 y métodos de uso de los mismos
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
CL2022002402A1 (es) Inhibidores del eif4e y sus usos
MA52900A (fr) Inhibiteurs à petites molécules de la famille jak de kinases
EA202192575A1 (ru) Соединения dbait в сочетании с ингибиторами киназ для лечения рака
DK3833665T3 (da) Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser